{"disease":{"id":"nephropathy","name":"nephropathy"},"drugs":{"marketed":[{"drug_id":"budesonide","indication_name":"Primary immunoglobulin A nephropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."},{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."},{"drug_id":"esaxerenone","indication_name":"Diabetic nephropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minnebro","generic_name":"esaxerenone","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting nephropathy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"allopurinol","indication_name":"Uric Acid Nephropathy Gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aloprim","generic_name":"ALLOPURINOL","company_name":"Casper Pharma Llc","drug_phase":"marketed","molecular_target":"Xanthine dehydrogenase/oxidase","drug_class":"Xanthine Oxidase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body."},{"drug_id":"potassium-bicarbonate","indication_name":"Prevention of Potassium Depletion - Potassium-Losing Nephropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POTASSIUM BICARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"iptacopan","indication_name":"Primary Immunoglobulin A Nephropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabhalta","generic_name":"IPTACOPAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Factor B","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G."}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05986474","title":"Development of Synthetic Medical Data Generation Technology to Predict Postoperative Complications","phase":"","overall_status":"COMPLETED","enrollment_count":410000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT00342927","title":"Family Investigation of Nephropathy and Diabetes (F.I.N.D.)","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT05132062","title":"Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI","phase":"","overall_status":"COMPLETED","enrollment_count":14616,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT01858532","title":"Study Of Diabetic Nephropathy With Atrasentan","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":5107,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04606056","title":"Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT02065791","title":"Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4401,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT05851222","title":"A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs (NeoAKI STOP)","phase":"","overall_status":"UNKNOWN","enrollment_count":4200,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT02575092","title":"The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Fuling Central Hospital of Chongqing City","has_results":false},{"nct_id":"NCT06355219","title":"Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines","phase":"","overall_status":"COMPLETED","enrollment_count":3932,"lead_sponsor_name":"Ali Aminian","has_results":false},{"nct_id":"NCT05685810","title":"Genetic Determinants of Kidney Disease in People of African Ancestry With HIV","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3029,"lead_sponsor_name":"King's College Hospital NHS Trust","has_results":false},{"nct_id":"NCT03929887","title":"KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03918824","title":"Influence of Iodinated Contrast Volume Injected During Coronarography on Contrast Nephropathy.","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Agnieszka Pozdzik","has_results":false},{"nct_id":"NCT06586203","title":"Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes","phase":"NA","overall_status":"RECRUITING","enrollment_count":2714,"lead_sponsor_name":"Optithera","has_results":false},{"nct_id":"NCT01105858","title":"Molecular and Clinical Profile of Diabetes Mellitus and Its Complications","phase":"","overall_status":"SUSPENDED","enrollment_count":2310,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT04858724","title":"The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05888909","title":"Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04879186","title":"Contrast Induced Nephropathy Among Vascular Patients Undergoing Lower Limb Angioplasty","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Singapore General Hospital","has_results":false},{"nct_id":"NCT03227835","title":"Contrast-Induced Nephropathy After Revision of the Prophylaxis Threshold","phase":"","overall_status":"COMPLETED","enrollment_count":1372,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04014153","title":"CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?","phase":"","overall_status":"COMPLETED","enrollment_count":1023,"lead_sponsor_name":"I.M. Sechenov First Moscow State Medical University","has_results":false},{"nct_id":"NCT03755700","title":"Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Rajaie Cardiovascular Medical and Research Center","has_results":false},{"nct_id":"NCT04931537","title":"Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07248891","title":"Type 2 Diabetes and Associated Factors in Mexico","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"Coordinación de Investigación en Salud, Mexico","has_results":false},{"nct_id":"NCT04662723","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":878,"lead_sponsor_name":"Fondazione Schena","has_results":false},{"nct_id":"NCT06833541","title":"Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease","phase":"","overall_status":"RECRUITING","enrollment_count":720,"lead_sponsor_name":"The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT07022626","title":"Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":688,"lead_sponsor_name":"Barts & The London NHS Trust","has_results":false},{"nct_id":"NCT03736018","title":"Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":688,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03627130","title":"The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":640,"lead_sponsor_name":"Barts & The London NHS Trust","has_results":false},{"nct_id":"NCT06564142","title":"Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":605,"lead_sponsor_name":"Alpine Immune Sciences Inc, A Subsidiary of Vertex","has_results":false},{"nct_id":"NCT05656261","title":"APOL1 Genetic Testing in African Americans","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"St. Louis University","has_results":false},{"nct_id":"NCT05271448","title":"Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography","phase":"NA","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"An-Najah National University","has_results":false},{"nct_id":"NCT05190848","title":"Correlation of Microbiome and Metabonomics With IgA Nephropathy","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT05248659","title":"Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy","phase":"PHASE2, PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":600,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT03886714","title":"Screening for Fabry Disease in Renal Transplantation","phase":"","overall_status":"TERMINATED","enrollment_count":592,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04195802","title":"Self-administered Questionnaire to Evaluate Salt and Potassium Diet of Patients Followed in Nephrology","phase":"","overall_status":"COMPLETED","enrollment_count":542,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04557462","title":"A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05248646","title":"Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":530,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT04578834","title":"Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":518,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06291376","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03329443","title":"The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Alhasan Mujtaba Abdul-Wahid","has_results":false},{"nct_id":"NCT05200871","title":"Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)","phase":"","overall_status":"COMPLETED","enrollment_count":487,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05839314","title":"Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06674577","title":"A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":476,"lead_sponsor_name":"Vera Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05528991","title":"Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy","phase":"","overall_status":"UNKNOWN","enrollment_count":474,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT06935357","title":"A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06483139","title":"Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03719339","title":"VIRTUUS Children's Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":445,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT04592406","title":"Data on the Prevention of Complications of Prophylactic Intravenous Hydration in Patients With eGFR < 30","phase":"","overall_status":"COMPLETED","enrollment_count":443,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06071533","title":"Effectiveness and Safety of Danshen Injection for Acute Kidney Injury in Primary Nephrotic Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":441,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT05797610","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}